Table 1 BCMA-targeted CAR T cell clinical trials in multiple myeloma
From: Any closer to successful therapy of multiple myeloma? CAR-T cell is a good reason for optimism
Signal domain | ORR | Efficacy | Side effect | Conditioning | Registration code | ||||
|---|---|---|---|---|---|---|---|---|---|
CR | sCR | PR | VGPR | CRS | CRES | ||||
CD28 | 20% | – | – | 1 | 1 | Gr3/4, 38% (high dose) | Gr3/4, 19% (high dose) | CP/Flu | NCT02215967 |
CD28 | 87% | – | – | – | – | Gr3, 14% | – | CP/Flu | ChiCTR-OPC-16009113 |
4-1BB | 85% | 3 | 12 | 4 | 9 | Gr1/2, 70% | Gr1/2, 39% Gr4, 3% | CP/Flu | NCT02658929 |
4-1BB | 86% | – | 1 | 2 | 3 | Gr1/2, 50% Gr3, 12.5% | Gr4, 12.5% | CP | NCT03274219 |
4-1BB | 88% | 39 | – | 8 | 3 | Gr1/2, 83% Gr3/4, 7% | Gr1, 1.8% | CP/Flu | NCT03090659 |
4-1BB | 88.2% | – | 13 | – | 2 | Mild, 10 Severe, 6 Very severe, 1 | – | CP/Flu | ChiCTR-ONH-17012285 |
4-1BB | 89% | 1 | 1 | 5 | 1 | Gr2, 1 | – | CP/Flu | NCT03288493 |
4-1BB | 100% | 1 | 2 | 1 | 2 | Gr1/2, 75% | Gr1/2, 38% | CP/Flu | NCT03430011 |
4-1BB | 100% | 3 | – | 4 | 6 | Gr1–3, 1 | none | CP/Flu | NCT03915184 |
4-1BB | 64% | – | – | – | – | Gr1/2, 40% Gr3, 20% | Gr2, 10% | CP/Flu | NCT03070327 |
4-1BB | 100% | 4 | – | 4 | 1 | Mild DLT | – | CP/Flu | ChiCTR1800018137 |
4-1BB | 79% | 3 | 4 | – | 2 | Mild | – | CP/Flu | NCT03093168 |
4-1BB | 48% | 1 | 1 | 5 | 5 | Gr3/4, 32% | Gr3/4, 12% | CP or none | NCT02546167 |
4-1BB | 100% | 1 | – | 3 | – | Under Gr3 | – | CP/Flu | NCT03661554 |
4-1BB | 95% | 3 | 9 | 3 | 5 | Gr1–2, 86% Gr3, 5% | – | CP/Flu | ChiCTR-OIC-17011272 |
OX40, CD28 | 80% | – | 1 | 2 | 1 | Mild | – | Bu-CP + ASCT | NCT03196414 |
OX40, CD28 | 100% | 3 | – | – | 6 | Mild | – | CP/Flu | NCT03455972 |